280 related articles for article (PubMed ID: 28429092)
21. PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG.
Conemans EB; Nell S; Pieterman CRC; de Herder WW; Dekkers OM; Hermus AR; van der Horst-Schrivers AN; Bisschop PH; Havekes B; Drent ML; Vriens MR; Valk GD
Endocr Pract; 2017 Jun; 23(6):641-648. PubMed ID: 28225311
[TBL] [Abstract][Full Text] [Related]
22. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome.
Norton JA; Alexander HR; Fraker DL; Venzon DJ; Gibril F; Jensen RT
Ann Surg; 2001 Oct; 234(4):495-505; discussion 505-6. PubMed ID: 11573043
[TBL] [Abstract][Full Text] [Related]
23. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany.
Scherübl H; Streller B; Stabenow R; Herbst H; Höpfner M; Schwertner C; Steinberg J; Eick J; Ring W; Tiwari K; Zappe SM
World J Gastroenterol; 2013 Dec; 19(47):9012-9. PubMed ID: 24379626
[TBL] [Abstract][Full Text] [Related]
24. Surgical aspects of gastrinoma in multiple endocrine neoplasia type 1.
Bartsch DK; Langer P; Rothmund M
Wien Klin Wochenschr; 2007; 119(19-20):602-8. PubMed ID: 17985096
[TBL] [Abstract][Full Text] [Related]
25. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
26. [Multiple Endocrine Neoplasia I (Wermers Syndrome), Forms of Clinical Manifestation, 5 Case Studies].
Drbalová K; Herdová K; Krejčí P; Nývltová M; Solař S; Vedralová L; Záruba P; Netuka D; Bavor P
Vnitr Lek; 2016; 62(9 Suppl 3):140-149. PubMed ID: 27734708
[TBL] [Abstract][Full Text] [Related]
27. Distinct Prognostic Factors in Sporadic and Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors.
Kfir SK; Halperin R; Percik R; Uri I; Halpern N; Shlomai G; Laish I; Tirosh A; Tirosh A
Horm Metab Res; 2021 May; 53(5):319-325. PubMed ID: 33878789
[TBL] [Abstract][Full Text] [Related]
28. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
29. Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.
Gonçalves TD; Toledo RA; Sekiya T; Matuguma SE; Maluf Filho F; Rocha MS; Siqueira SA; Glezer A; Bronstein MD; Pereira MA; Jureidini R; Bacchella T; Machado MC; Toledo SP; Lourenço DM
J Clin Endocrinol Metab; 2014 Jan; 99(1):E89-96. PubMed ID: 24178797
[TBL] [Abstract][Full Text] [Related]
30. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
31. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature.
Gibril F; Schumann M; Pace A; Jensen RT
Medicine (Baltimore); 2004 Jan; 83(1):43-83. PubMed ID: 14747767
[TBL] [Abstract][Full Text] [Related]
32. [Operative management and long-term survival in patients with neuroendocrine tumors of the pancreas--experience with 144 patients].
Fendrich V; Habbe N; Celik I; Langer P; Zielke A; Bartsch DK; Rothmund M
Dtsch Med Wochenschr; 2007 Feb; 132(5):195-200. PubMed ID: 17252361
[TBL] [Abstract][Full Text] [Related]
33. Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms.
Berardi R; Torniai M; Partelli S; Rubini C; Pagliaretta S; Savini A; Polenta V; Santoni M; Giampieri R; Onorati S; Barucca F; Murrone A; Bianchi F; Falconi M
PLoS One; 2018; 13(5):e0197035. PubMed ID: 29787601
[TBL] [Abstract][Full Text] [Related]
34. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines.
Goudet P; Dalac A; Le Bras M; Cardot-Bauters C; Niccoli P; Lévy-Bohbot N; du Boullay H; Bertagna X; Ruszniewski P; Borson-Chazot F; Vergès B; Sadoul JL; Ménégaux F; Tabarin A; Kühn JM; d'Anella P; Chabre O; Christin-Maitre S; Cadiot G; Binquet C; Delemer B
J Clin Endocrinol Metab; 2015 Apr; 100(4):1568-77. PubMed ID: 25594862
[TBL] [Abstract][Full Text] [Related]
35. Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors.
Nell S; Borel Rinkes IHM; Verkooijen HM; Bonsing BA; van Eijck CH; van Goor H; de Kleine RHJ; Kazemier G; Nieveen van Dijkum EJ; Dejong CHC; Valk GD; Vriens MR;
Ann Surg; 2018 Feb; 267(2):352-356. PubMed ID: 27811505
[TBL] [Abstract][Full Text] [Related]
36. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.
Ito T; Igarashi H; Uehara H; Berna MJ; Jensen RT
Medicine (Baltimore); 2013 May; 92(3):135-181. PubMed ID: 23645327
[TBL] [Abstract][Full Text] [Related]
37. The Management of Neuroendocrine Tumors of the Lung in MEN1: Results From the Dutch MEN1 Study Group.
van den Broek MFM; de Laat JM; van Leeuwaarde RS; van de Ven AC; de Herder WW; Dekkers OM; Drent ML; Kerstens MN; Bisschop PH; Havekes B; Hackeng WM; Brosens LAA; Vriens MR; Buikhuisen WA; Valk GD
J Clin Endocrinol Metab; 2021 Jan; 106(2):e1014-e1027. PubMed ID: 33135721
[TBL] [Abstract][Full Text] [Related]
38. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
[TBL] [Abstract][Full Text] [Related]
39. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
[TBL] [Abstract][Full Text] [Related]
40. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
